Current Issues in Managing Erectile Dysfunction Monograph Enhancing Treatment Adherence and Outcomes With Erectile Dysfunction Pharmacotherapies
This monograph, fifth in the Current Issues series, describes effective management of erectile dysfunction with an individualized regimen. Economic barriers, psychosocial outcomes, tailoring therapy to the patient’s lifestyle and needs, and managing patient response are discussed.
Please circle the appropriate rating number, complete the posttest and evaluation form and fax to: 877-403-5765; or mail to:
CIEF, CogniMed Inc., 70 South Orange Avenue
Suite 200
Livingston, NJ 07039
• Stanley E. Althof, PhD
• Gregory A. Broderick, MD
• Raymond C. Rosen, PhD
• Ridwan Shabsigh, MD
Although CME is no longer offered for this program, it is available for your use as reference material.
Novel Treatment Paradigms: Advances in Erectile Dysfunction Management With Phosphodiesterase Type 5 Inhibitors
PDE5 inhibitors offer more than an on-demand solution to improving patient outcomes. For example, alternative dosing regimens have been shown to prompt response in men who did not respond to on-demand doses. Furthermore, PDE5 inhibitors impart endothelial and cardiovascular benefits, and recent studies indicate that PDE5 inhibitors benefit men with lower urinary tract symptoms (LUTS) and benign prostatic hypertrophy (BPH). This program will feature presentations that compare on-demand and scheduled dosing regimens of PDE5 inhibitors, particularly for men with comorbid conditions, as they were delivered at a satellite symposium during the 2007 American Urological Association Annual Meeting in Anaheim, California.
Click here to view monograph.
Please remember, in order to receive CME credit for this program you must complete the evaluation and posttest online or download the PDF file.
